Search Bar & Filters
Found 31 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the relationship between inflammatory markers in dental pulp and the success of full pulpotomy treatment for moderate and severe pulpitis caused by extremely deep caries in mandibular molars. This prospective cohort study aims to improve understanding of how immune response intensity relates to treatment outcomes, given that current clinical methods to diagnose pulp inflammation are subjective and may not reflect true biological status. The study focuses on key inflammatory markers, IL-1Beta and IL-6, which play crucial roles in the progression of pulp inflammation. The study involves medically healthy adults aged 18 to 40 years who have extremely deep caries reaching the full thickness of dentine in permanent mandibular molars without a radiopaque zone separating the lesion from the pulp, and with a PAI score of 2 or less. Participants are diagnosed with moderate or severe pulpitis based on clinical and radiographic exams and pulp testing. The treatment includes full pulpotomy, where the pulp chamber is fully opened and pulp tissue removed to the root canal orifices, with pulpal blood collected for biomarker measurement. Hemostasis is achieved with sodium hypochlorite, and Mineral Trioxide Aggregate MTA is used as a pulp capping material followed by composite restoration. Participants will be monitored over 12 to 18 months, with clinical and radiographic success of full pulpotomy assessed at 6 and 12 months. Researchers will measure IL-1Beta and IL-6 levels in pulpal blood using ELISA to correlate with treatment outcomes. Statistical analyses will evaluate associations between inflammatory marker levels and treatment success. This study may help provide objective biological data to guide treatment decisions for deep caries with pulpitis.
Actively Recruiting
Researchers are evaluating the safety, immune response, and consistency between different vaccine lots of BBV87, an inactivated Chikungunya virus vaccine, in healthy individuals aged 12 to 65 years. This Phase IIIII clinical trial is randomized, observer-blind, and placebo-controlled, aiming to understand how well the vaccine works and its safety profile across multiple study centers. Participants will be randomly assigned to receive one of three lots of the BBV87 vaccine or a placebo. Each subject will receive two doses of 40 micrograms administered as injections into the deltoid muscle of the arm, with the second dose given about 28 days after the first. Safety data will be reviewed by an independent board during the study to ensure participant protection. During the study, participants will attend visits for vaccination and follow-up assessments, including blood tests to measure antibody levels against the virus 28 days after each dose. Researchers will monitor for any adverse events for up to 11 months post-vaccination. The main outcomes measured include immune response levels and the percentage of participants who develop antibodies, along with the safety and tolerability of the vaccine.
Actively Recruiting
Researchers are conducting a Phase I open-label study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose of AUR107 in adults with relapsed advanced malignancies. The study focuses on patients with selected advanced solid tumors, such as non-small cell lung cancer, gastric cancer, urothelial cancer, kidney cancer, colon cancer, and esophageal cancer, who have no curative or life-prolonging treatment options left. This first-in-human trial aims to find the best dose of AUR107 using a traditional dose-escalation design. Participants will receive oral AUR107 once daily at escalating doses ranging from 5 mg to 200 mg. The trial follows a 33 dose escalation design to evaluate safety and determine the optimal biological dose based on safety, pharmacokinetics, and pharmacodynamics data. The study is multicenter and includes dose expansion following dose escalation. During the study, participants will be closely monitored for dose-limiting toxicities and treatment-related adverse events over 28-day cycles. Researchers will measure pharmacokinetic parameters such as maximum concentration, time to maximum concentration, area under the curve, mean residence time, and elimination half-life at various time points under fasting and fed conditions. Safety assessments and clinical evaluations will be conducted throughout the study, which is expected to continue until June 2027.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose of an oral drug called AUR108 in adult patients with relapsed advanced lymphomas, including Non-Hodgkin and Hodgkin lymphoma. This Phase 1, open-label, first-in-human study focuses on patients who have no available curative or life-prolonging treatments left and have exhausted all effective local therapies. The study uses a traditional dose-escalation design to determine the best dose of AUR108 based on safety and biological data. Participants will receive AUR108 orally with doses planned at 50, 90, 150, 220, and 300 mg in a cycle of 3 days of dosing followed by 4 days off each week. The study follows a 33 dose-escalation method to evaluate safety and drug behavior in the body and to select the optimal biological dose. This is a multicenter trial with dose expansion planned after the initial dose-escalation phase. During the study, participants will be closely monitored for dose-limiting toxicities during the first 28-day cycle and treatment-related adverse events throughout the trial, which may last about a year. Researchers will collect blood samples to measure drug levels and effects at multiple time points, including days 1, 8, and 17. Participants will undergo safety assessments, organ function tests, and evaluations of their lymphoma status to track treatment impact and side effects over time.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide at different dose levels compared to a placebo in adults with uncontrolled moderate to severe asthma. The study aims to understand how brenipatide impacts asthma control and exacerbation rates over time. This phase 2, randomized, double-blind trial involves participants aged 18 to 75 years who have a history of asthma and recent asthma exacerbations. Participants will receive either one of two doses of brenipatide or a placebo, all administered by subcutaneous injection. The treatment period lasts 52 weeks, during which the effects of the study drug on asthma symptoms and lung function will be monitored. The study includes screening, treatment, and follow-up phases, with the overall participation lasting about 65 weeks. During the trial, participants will undergo assessments such as lung function tests, health questionnaires, and monitoring for asthma exacerbations and medication use. Blood samples may be collected to study the drugs behavior in the body and the immune response. Researchers will track safety and treatment effects throughout the study and during follow-up to understand the long-term impact of brenipatide on asthma control.
Actively Recruiting
Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.
Actively Recruiting
Researchers are conducting a Phase 1 study to evaluate the safety and tolerability of SBO-154 in adults with advanced solid tumors who have either not responded to or cannot tolerate standard treatments. The study aims to find the highest dose of SBO-154 that patients can safely tolerate and then further assess its safety in specific advanced cancers. The study is divided into two parts. In Part 1, participants receive escalating doses of SBO-154 administered intravenously every three weeks to determine the maximum tolerated dose. In Part 2, the safety of the selected doses from Part 1 is further evaluated in patients with particular types of advanced solid tumors. Treatment continues with dosing every three weeks during the study period. Participants will be closely monitored through scheduled visits involving laboratory tests and assessments to track any dose-limiting toxicities and treatment-related adverse events up to 30 days after the last dose. Researchers will also evaluate tumor response using imaging every six weeks for up to 12 months and monitor the presence of anti-drug antibodies for up to one year. The overall study duration extends through 2030, with ongoing safety and response evaluations.
Actively Recruiting
Healthy Volunteer
Researchers are investigating how facial growth patterns affect the relapse of teeth alignment after orthodontic treatment during the retention phase. The study focuses on differences between horizontal and vertical growers, hypothesizing that horizontal growers show more vertical tooth movement, especially in overbite, while long-faced individuals may experience more relapse in lower front teeth alignment and crowding. Understanding these factors helps predict and prevent relapse, aiming to improve long-term orthodontic treatment stability. Participants are grouped based on facial growth type vertical growers with a fixed mandibular plane angle FMA of 26 degrees or more, and horizontal growers with an FMA of 24 degrees or less. All participants have completed fixed orthodontic treatment and will receive a Beggs retainer formed by conventional methods within 24 hours of debonding. The study compares 3-dimensional dentitional changes in the teeth over a 12-month retention period using advanced 3D superimposition techniques. During the study, participants will be monitored for tooth movement in three planes of space antero-posterior, vertical, and transverse. Researchers will assess these changes using measurements like the Littles irregularity index and PAR score to evaluate occlusion and alignment. Regular follow-ups will track retention compliance, oral hygiene, and periodontal health. The main outcome is the comparison of 3D dentitional changes over 12 months to understand how facial growth patterns influence orthodontic relapse and stability.
Actively Recruiting
The research investigates the clinical and radiographic results of direct pulp capping in mature permanent mandibular molars with reversible pulpitis, focusing on comparing outcomes between deep and extremely deep carious lesions. The study aims to assess the success of this treatment in teeth with different depths of caries and to evaluate pain after the procedure, involving adults aged 18 to 40 years. There is a need to clarify how caries depth affects treatment success, as current data are limited and show varying success rates. Participants will receive direct pulp capping treatment after a clinical diagnosis of reversible pulpitis is confirmed. The procedure includes cleaning and controlling bleeding at the pulp exposure site with 3% sodium hypochlorite, applying a layer of ProRoot MTA over the lesion followed by resin-modified glass ionomer cement, and final restoration with composite resin. Two groups are studied one with deep carious lesions and one with extremely deep lesions. Follow-up includes clinical and radiographic assessments at 7 days, 6 months, and 12 months to evaluate treatment success. During the study, participants will be monitored for pain levels at baseline and daily for one week after treatment. Radiographic images will be taken at 6 and 12 months to assess the tooths condition. Success rates will be measured at 12 months, with researchers tracking bleeding control time during treatment and ensuring healthy periodontal status. The total participation period may last up to one year, with regular evaluations to monitor healing and any complications.
Actively Recruiting
Healthy Volunteer
Researchers are comparing two dental treatmentsindirect and direct pulp cappingin adult patients with deeply decayed mature mandibular molars showing signs of moderate pulp inflammation called moderate pulpitis. This trial aims to evaluate which method better preserves tooth vitality and reduces pain. The study focuses on teeth with clinical and radiographic signs that suggest moderate pulpitis, a condition where the pulp shows prolonged sensitivity and dull pain but may still recover if treated properly. The trial involves two treatment approaches. One group will receive partial removal of the decayed tissue followed by indirect pulp capping, where a protective material called MTA is applied over the remaining dentin, then sealed with a resin and composite restoration. The other group will undergo complete caries removal, which may expose the pulp, followed by direct pulp capping where the exposed pulp is treated with MTA, sealed with resin, and restored with composite. Both treatments are performed under sterile conditions to promote healing. Participants will be monitored over 12 months to assess clinical and X-ray success of the treatments. Pain levels will be recorded daily for one week after treatment to evaluate reduction in discomfort. Follow-up visits will include pulp sensibility tests and radiographs to check tooth health and healing. This trial lasts for one year, with regular check-ups to track outcomes and treatment success in these dental procedures.
1-10 of 31
1